Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Tivic Health Systems, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TICKER SYMBOL TO CHANGE FROM TIVC TO VBIO EFFECTIVE APRIL 28, 2026; COMPANY ADVANCING ENTOLIMOD TOWARD BARDA FUNDING AND STRATEGIC NATIONAL STOCKPILE PROCUREMENT WHILE VELOCITY BIOWORKS CDMO BUILDS INDEPENDENT REVENUE BASE SAN ANTONIO, APRIL 23, 2026 /PRNEWSWIRE/ --TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC) TODAY ANNOUNCED IT IS CHANGING ITS CORPORATE NAME TO VALION BIO, INC. AND ITS NASDAQ TICKER SYMBOL FROM TIVC TO VBIO, EFFECTIVE AT MARKET OPEN ON TUESDAY, APRIL 28, 2026. THE CUSIP NUMBER FOR THE COMPANY'S COMMON STOCK WILL REMAIN UNCHANGED.

TIVIC HEALTH SYSTEMS REBRANDS AS VALION BIO, REFLECTING COMPLETED TRANSFORMATION INTO A LATE-STAGE BIOPHARMACEUTICAL COMPANY WITH GOVERNMENT-BACKED ASSET AND POTENTIAL MULTIPLE REVENUE STREAM MODEL

SAN ANTONIO, APRIL 15, 2026 /PRNEWSWIRE/ -- TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A CLINICAL-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED IT HAS BEEN SELECTED TO PRESENT AT THE U.S. DEPARTMENT OF WAR'S TECH WATCH PROGRAM ON MAY 7, 2026. THE TECH WATCH INITIATIVE IDENTIFIES EMERGING TECHNOLOGIES WITH HIGH-VALUE DEFENSE AND DUAL-USE APPLICATIONS.

TIVIC HEALTH SELECTED TO PRESENT ENTOLIMOD AS A RADIATION COUNTERMEASURE AND ITS PLANS FOR AN ORAL TRANSMUCOSAL PROGRAM TO THE DEPARTMENT OF WAR TECH WATCH PROGRAM ON MAY 7TH

SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 31, 2026 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A CLINICAL-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED IT HAS RECEIVED A FORMAL REQUEST FOR INFORMATION (RFI) FROM THE UKRAINIAN MINISTRY OF HEALTH. THE RFI INITIATES THE FORMAL EVALUATION OF ENTOLIMOD TIVIC'S LATE-STAGE TOLL-LIKE RECEPTOR 5 (TLR5) AGONIST FOR POTENTIAL INCLUSION IN UKRAINE'S NATIONAL STRATEGIC RESERVES AS A COUNTERMEASURE AGAINST ACUTE RADIATION SYNDROME (ARS).

TIVIC RECEIVES FORMAL REQUEST FOR INFORMATION FROM UKRAINIAN MINISTRY OF HEALTH REGARDING STRATEGIC STOCKPILING OF ENTOLIMOD

PRESENTATION WILL COVER RECENT CORPORATE MILESTONES INCLUDING SECURING AGREEMENT WITH NIAID SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 27, 2026 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A CLINICAL-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT ITS NEWLY APPOINTED CHIEF EXECUTIVE OFFICER, MICHAEL K HANDLEY, WILL DELIVER A CORPORATE UPDATE AT THE EMERGING GROWTH VIRTUAL CONFERENCE TAKING PLACE APRIL 1-2, 2026. DURING THE VIRTUAL CONFERENCE, MR.

TIVIC CEO TO PRESENT AT THE UPCOMING EMERGING GROWTH'S APRIL 2026 VIRTUAL CONFERENCE

ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE (AFRRI) WILL CONDUCT THE GASTROINTESTINAL ACUTE RADIATION SYNDROME (GI-ARS) STUDY SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 26, 2026 / TIVIC HEALTH SYSTEMS INC. (NASDAQ:TIVC), A CLINICAL-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED IT HAS ENTERED INTO AN AGREEMENT WITH THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), PART OF THE NATIONAL INSTITUTES OF HEALTH, TO SPONSOR AND CONDUCT A SERIES OF PRECLINICAL STUDIES EVALUATING ENTOLIMOD FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME (GI-ARS). THE PROGRAM IS EXPECTED TO SUPPORT TIVIC'S DEVELOPMENT STRATEGY FOR ENTOLIMOD AS A MEDICAL COUNTERMEASURE FOR ACUTE RADIATION SYNDROME (ARS).

TIVIC SECURES NIAID NON-CLINICAL EVALUATION AGREEMENT FOR ENTOLIMOD, TARGETING GASTROINTESTINAL ACUTE RADIATION SYNDROME

COMPLETES STRATEGIC TRANSFORMATION INTO AN IMMUNOTHERAPY COMPANY AND CONTINUES TO ADVANCE ENTOLIMOD PLATFORM TOWARD POTENTIAL FUNDING PARTNERSHIPS CONFERENCE CALL TO BE HELD TODAY AT 1:30 PM PT / 4:30 PM ET SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 25, 2026 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A DEVELOPMENT-STAGE IMMUNOTHERAPY COMPANY, TODAY REPORTED FINANCIAL AND OPERATIONAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE HIGHLIGHTING THE COMPANY'S STRATEGIC TRANSFORMATION AND FOCUS ON THE DEVELOPMENT OF ITS ENTOLIMOD PLATFORM. "2025 WAS A DEFINING YEAR FOR TIVIC AS WE MARKED OUR TRANSFORMATION INTO A FOCUSED IMMUNOTHERAPY COMPANY ANCHORED BY ENTOLIMOD AND ITS NEXT-GENERATION MOLECULE, ENTOLASTA," SAID MICHAEL K.

TIVIC REPORTS FULL YEAR 2025 RESULTS

SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 24, 2026 / TIVIC HEALTH SYSTEMS (NASDAQ:TIVC) DEAR VALUED SHAREHOLDERS, AS I ASSUME THE ROLE OF CHIEF EXECUTIVE OFFICER AT TIVIC, MY IMMEDIATE PRIORITY IS TO ESTABLISH A TRANSPARENT DIALOGUE WITH YOU REGARDING OUR CURRENT STANDING, OUR STRATEGIC PIVOT, AND THE LONG-TERM VISION WE ARE EXECUTING. FIRST, I WANT TO THANK THE BOARD OF DIRECTORS FOR THEIR CONFIDENCE AND SUPPORT.

TIVIC HEALTH CEO LETTER TO SHAREHOLDERS

SAN ANTONIO, TX / ACCESS NEWSWIRE / MARCH 20, 2026 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A LATE-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT IT WILL REPORT ITS YEAR-END FINANCIAL RESULTS FOR 2025 VIA PRE-RECORDED CONFERENCE CALL AND WEBCAST ON WEDNESDAY, MARCH 25, 2026 AT 1:30 PM PT / 4:30 PM ET. CONFERENCE CALL AND WEBCAST INFORMATION TELECONFERENCE DETAILS: TOLL FREE: 888-506-0062INTERNATIONAL: 973-528-0011PARTICIPANT ACCESS CODE: 910220 WEBCAST LINK HTTPS://WWW.WEBCASTER5.COM/WEBCAST/PAGE/2865/53678 AN AUDIO REPLAY OF THE CALL WILL BE AVAILABLE FOR THE NEXT 90 DAYS FROM THE INVESTOR PAGE ON THE TIVIC WEBSITE AT HTTPS://TIVICHEALTH.COM/INVESTOR/.

TIVIC TO REPORT 2025 YEAR-END FINANCIAL RESULTS VIA CONFERENCE CALL AND WEBCAST ON MARCH 25TH AT 1:30PM PT / 4:30PM ET

SAN FRANCISCO, CA / ACCESS NEWSWIRE / MARCH 4, 2026 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC) ("TIVIC" OR THE "COMPANY"), A LATE-STAGE IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPOINTED MICHAEL K. HANDLEY AS CHIEF EXECUTIVE OFFICER OF TIVIC, EFFECTIVE IMMEDIATELY.

BIOTECH VETERAN MICHAEL K. HANDLEY NAMED CEO OF TIVIC HEALTH SYSTEMS TO SPEARHEAD STRATEGIC EXPANSION IN BIOPHARMA

INITIAL PRESENTATION ON JANUARY 26, 2026 S HOWCASED ENTOLIMOD'S POTENTIAL TO MITIGATE AND PREVENT BOTH GASTROINTESTINAL AND HEMATOPOIETIC INJURY FROM IONIZING RADIATION EXPOSURE. FREMONT, CA / ACCESS NEWSWIRE / FEBRUARY 18, 2026 / TIVIC (NASDAQ:TIVC), A LATE-STAGE IMMUNO-THERAPEUTICS COMPANY, TODAY ANNOUNCED THAT A SECOND, FOLLOW-UP MEETING WITH THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) HAS BEEN SCHEDULED FOR MARCH 10, 2026, TO CONTINUE DISCUSSIONS FOCUSED ON CLINICAL DATA AND THE POTENTIAL FOR FUNDING AND, ULTIMATELY, STOCKPILING ENTOLIMOD FOR ACUTE RADIATION SYNDROME (ARS).

Tivic Health Systems, Inc.

TIVC

Price

Financial Reports

No items found.

Press Releases

Tivic Health Systems, Inc.

TIVC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TIVC